A class of medications born from adult diabetes care has quietly entered the world of childhood medicine, with GLP-1 prescriptions for children under twelve rising more than 30,000 percent since 2019. The absolute numbers remain small, but the trajectory reflects something larger — a cultural and clinical hunger for solutions to pediatric obesity that has outpaced the science meant to guide it. As these drugs reshape how adults understand weight and health, their reach toward younger and younger patients asks an old question in a new form: how much certainty must we have before we act, and who
GLP-1 prescriptions for children surge over 30,000% since 2019
Children under 12 are being prescribed weight-loss medications, raising concerns about developmental and health impacts on a vulnerable population.